RNS Number : 1850Z
Omega Diagnostics Group PLC
13 September 2022
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Investor presentation and Confirmation of AGM

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, provides the following details on the Investor presentation and Company's Annual General Meeting ("AGM").

 

Investor presentation

Jag Grewal (CEO) and Chris Lea (CFO) will provide a live presentation covering the preliminary results, which were issued yesterday, via the Investor Meet Company platform on Wednesday 14 September 2022 at 12pm.

 

The presentation is open to all existing and potential shareholders. Investors can sign up to Investor Meet Company for free and add to meet Omega Diagnostics Group plc via:

 

https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor

 

Investors who already follow Omega Diagnostics Group plc on the Investor Meet Company platform will automatically be invited.

 

Annual General Meeting

The Company confirms it will host its AGM at Poets House, St Mary's Street, Ely, CB7 4EY on Wednesday 26 October 2022 at 11.00am.

 

 

Contacts: 

Omega Diagnostics Group PLC                         

www.omegadx.com

Jag Grewal, Chief Executive Officer                            

via Walbrook PR

Chris Lea, Chief Financial Officer




finnCap Ltd                                              

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)


Alice Lane/ Charlotte Sutcliffe (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDGGDCRBBDGDD